TITLE:
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

CONDITION:
Chronic Hepatitis C

INTERVENTION:
peginterferon alfa-2b (SCH 54031)

SUMMARY:

      The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no
      treatment for the prevention of disease progression in adult subjects with compensated
      cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a
      interferon plus ribavirin.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  Age at entry 18-65 years;

          -  Non-responders to previous treatment (minimum of 3 months) with an alpha interferon
             plus ribavirin;

          -  Liver biopsy demonstrating cirrhosis

        Exclusion Criteria:

          -  Any other cause for liver disease other than chronic hepatitis C;

          -  History or presence of complications of cirrhosis;

          -  Alcohol or illicit drug abuse or treatment with methadone within the past 2 years;

          -  Diseases or conditions that could interfere with participation in the study
      
